Find your next M&A target

Target Asia + Worldwide M&A projects with our guidance on matching, planning, due diligence & implementation.

Project details

Korean stem cell therapy company seeks USD 20 million B-round financing

Project region South Korea
Industry Biomedicine
Total value of the target N/A
Expected target net rate of return after deducting all taxes and fees N/A
Validity period of pending order 365


Project highlights stem cell therapy - industry leader - USD 80 million valuation
Project description

The Korean company provides three types of stem cell therapies. First, its Natural Killer ("NK") immune cell therapy is used for treatment of prostate cancer, ovarian cancer and lung cancer. Second, its mesenchymal stem cell ("MSC") therapy is used for treatment of degenerative arthrits of the knee. Third, its TSC differentiated cell induction technology is used for treatment of Charcot-Marie-Tooth disease. All of these have completed Phase I clinical trials in 2021. The company is a leader in the industry of immune cell therapy but also in the industry of second-generation cytogenetic therapy. Its current value is about USD 80 million. The company seeks USD 20 million B-round financing.

Enquire for more information about our services, and how we can help solve challenges for your organization

Contact Us
The code is case-sensitive